Key Insights• According to the research report, "India Cardiovascular Devices Market Outlook, 2031," published by Actual Market Research, the India Cardiovascular Devices Market is anticipated to add to more than 1.24 Billion by 2026-31.• The Indian cardiovascular device market is experiencing rapid expansion fueled by indigenous technological innovation, expanding public health insurance schemes, and a high disease burden. Local manufacturers are achieving significant breakthroughs in structural heart therapies and bio-absorbable vascular technology. Domestic companies like Sahajanand Medical Technologies (SMT) and Meril Life Sciences have successfully commercialized indigenous Transcatheter Aortic Valve Replacement (TAVR) systems such as the Myval transcatheter heart valve series and bioresorbable scaffolds.• By capping the selling prices of essential items like drug-eluting stents (DES) and orthopedic/cardiac implants under the National List of Essential Medicines (NLEM), the NPPA has driven rapid volume adoption across both public and private sectors. While price ceilings on drug-eluting stents (capped at approximately INR 38,933) have compressed gross profit margins for multinational vendors, they have vastly increased procedural accessibility. To maintain profitability, manufacturers are shifting commercial focus toward non-capped, high-value advanced sub-segments such as intravascular ultrasound (IVUS), fractional flow reserve (FFR) wires, structural heart valves, and electrophysiology mapping platforms.• Digital health infrastructure and AI-driven diagnostic platforms are rapidly bridging the gap between urban cardiac centers and rural healthcare networks. Driven by the expansion of the Ayushman Bharat Digital Mission (ABDM) and private healthcare networks, cardiologists are deploying cloud-connected continuous ECG patches, smart telemetry monitors, and remote implantable loop recorders (ILRs) to catch transient arrhythmias early.

Machine learning models integrated into these diagnostic systems automatically filter continuous telemetry for silent atrial fibrillation and early markers of heart failure.Market Outlook• The market outlook point highlights the rapid migration of routine cardiovascular diagnostics, outpatient electrophysiology, and low-complexity percutaneous interventions toward specialized day-surgery centers, ambulatory care facilities, and community healthcare networks. Supported by private healthcare expansion and government initiatives aimed at relieving pressure on overcrowded public tertiary hospitals, capital is being deployed to build specialized regional cardiology centers. Medical device vendors providing compact, single-use, highly portable diagnostic hardware alongside cloud-based telemetry platforms will capture the strongest procurement traction across both public tender frameworks and expanding private hospital networks.• Crucial industry trade bodies and professional organizations such as the Medical Technology Association of India (MTaI), the Association of Indian Medical Device Industry (AiMeD), and the Cardiological Society of India (CSI) continue to influence clinical practice guidelines and national policy, while leading domestic and multinational companies such as Meril Life Sciences, Sahajanand Medical Technologies (SMT), Medtronic, Abbott Laboratories, Boston Scientific, Edwards Lifesciences, BIOTRONIK, and Terumo Corporation drive ongoing commercial and clinical deployment across India.Market DynamicsDriver: High cardiovascular disease burden, PM-JAY expansion, and PLI scheme incentivesThe primary catalyst fueling the Indian cardiovascular devices market is the severe national incidence of ischemic heart disease, stroke, and chronic heart failure which together represent the leading cause of mortality nationwide. This epidemiological pressure is paired with aggressive government initiatives designed to democratize treatment access while fostering domestic manufacturing. Challenge: NPPA price caps, margin compression, and shortage of skilled specialistsThe primary structural challenge facing device manufacturers and distributors in India is navigating strict price control mechanisms alongside severe clinical infrastructure gaps. Under the National Pharmaceutical Pricing Authority (NPPA) and the National List of Essential Medicines (NLEM), government price ceilings mandate strict caps on essential interventional hardware like drug-eluting stents (DES) and cardiac implants.Trend: Indigenous structural heart innovations, ABDM infrastructure, and AI remote telemetryA dominant trend transforming the Indian cardiovascular device landscape is the rapid growth of locally developed structural heart technologies paired with AI-driven digital remote monitoring. Domestic medtech pioneers are achieving major breakthroughs in transcatheter aortic valve replacement (TAVI/TAVR) platforms and bioresorbable scaffolds, delivering clinically proven performance at a fraction of the cost of imported alternatives.Segment Analysis India Cardiovascular Devices By Device Type• India’s therapeutic and surgical cardiovascular-device segment is characterized by rapid movement toward indigenous manufacturing, risk-based regulation, and increasingly sophisticated interventional technologies.

The portfolio includes coronary stents, balloons and catheters, pacemakers, ICDs, heart valves, electrophysiology systems, ventricular-assistance technologies, and surgical devices. CDSCO classifies medical devices according to risk, with cardiovascular products subject to dedicated classification that is periodically updated; notably, CDSCO published a draft cardiovascular and neurological risk-classification list for stakeholder comments in 2025.• India’s diagnostic and monitoring segment is evolving from conventional ECG, Holter, blood-pressure, and hospital monitoring toward connected, software-enabled, and potentially continuous cardiovascular surveillance. India’s regulatory definition explicitly includes software when it serves medical-device purposes, and CDSCO issued dedicated guidance on medical-device software in 2026. This creates an expanding ecosystem in which wearable monitoring, remote physiological assessment, digital interpretation, and connected cardiac devices can complement traditional hospital diagnostics. India Cardiovascular Devices By Application• India’s CAD device segment is built around high-throughput interventional cardiology combined with increasingly sophisticated catheter-based technologies. The ecosystem includes coronary angiography, guidewires, balloons, drug-eluting stents, intravascular imaging, atherectomy and other intervention-support technologies. A distinctive characteristic is the strong role of domestic device development in coronary intervention, supported by India’s evolving regulatory framework and local manufacturing initiatives.• India’s heart-failure device segment is increasingly focused on long-term disease management through implantable therapy, mechanical support, and physiological monitoring.

Cardiac-resynchronization systems, ICDs, pacemakers, ventricular-assistance technologies, and emerging sensor-based monitoring solutions address different stages of heart-failure management. A particularly distinctive development is regulatory attention to novel biomarkers and sensor-based monitoring: CDSCO’s cardiovascular expert committee recently reviewed a sensor-based system intended to monitor interstitial-fluid lactate in patients with advanced heart failure.• India’s cardiac-arrhythmia segment combines electrophysiology, catheter ablation, implanted rhythm-management systems, and increasingly sophisticated pacing technologies. Pacemakers, ICDs, CRT systems, mapping and ablation platforms, and implantable monitoring devices address different stages of rhythm management. The regulatory pipeline demonstrates continuing technological development: CDSCO has considered clinical investigation of a conduction-system-pacing display research system designed to support lead placement, reflecting the movement toward more physiologically targeted pacing approaches.• India’s structural-heart segment is characterized by growing adoption of advanced valve technologies, minimally invasive intervention, and locally generated clinical evidence. The segment encompasses surgical and transcatheter valves, valve-repair systems, delivery catheters, occlusion technologies, and advanced imaging used for anatomical assessment and procedural guidance. A notable market characteristic is the increasing regulatory consideration of domestically manufactured structural-heart products: CDSCO’s cardiovascular expert committee recommended manufacturing permission for a mitral valve after reviewing clinical investigation evidence generated in India, with continued post-market follow-up required.• Other cardiovascular applications encompass vascular intervention, emergency cardiac care, mechanical circulatory support, congenital-heart procedures, specialized imaging, and digitally enabled cardiovascular technologies.

The segment is particularly diverse because India’s medical-device definition covers instruments, implants, materials, software, and accessories intended for diagnosis, monitoring, treatment, physiological support, or life support. Consequently, cardiovascular innovation extends beyond conventional implants into software-driven monitoring, advanced sensors, and connected devices. India Cardiovascular Devices By End-User • Hospitals and cardiac centers remain the principal environment for complex cardiovascular intervention, implantation, electrophysiology, cardiac surgery, intensive monitoring, and advanced imaging. These facilities provide catheterization laboratories, operating theatres, cardiac intensive-care infrastructure, specialized imaging, and multidisciplinary teams required for high-risk procedures. The Indian regulatory system also places particular emphasis on safety, performance, licensing, clinical investigation, and post-market surveillance for medical devices, making hospitals important not only as treatment sites but also as environments for clinical evidence generation and post-market follow-up of advanced cardiovascular technologies.• India does not exactly replicate the U.S. ASC model; outpatient cardiovascular procedures are generally distributed across day-care hospitals, hospital outpatient departments, specialty facilities, and other ambulatory-care models. The increasing use of minimally invasive cardiovascular technologies creates opportunities for selected interventions to move toward shorter-stay pathways when clinically appropriate.

Devices that reduce procedural trauma, simplify intervention, support predictable recovery, and enable efficient post-procedure monitoring are therefore particularly relevant to this end-user environment, while complex implants continue to require hospitals with emergency and intensive-care capabilities.• Specialty clinics are increasingly relevant for cardiac diagnostics, electrophysiology, arrhythmia follow-up, heart-failure management, preventive cardiology, rehabilitation, and chronic monitoring. Portable ECG systems, Holter monitors, wearable technologies, and connected physiological-monitoring platforms can extend cardiovascular assessment beyond tertiary hospitals. India’s regulatory framework explicitly covers software and connected medical-device functionality, while the emergence of sensor-based cardiovascular monitoring under CDSCO review points toward greater use of technology in specialist outpatient management.• India’s home-care cardiovascular-device segment is developing around wearable monitoring, portable diagnostics, remote physiological surveillance, and connected chronic-care technologies. Home-based monitoring can reduce dependence on repeated facility visits for selected patients and can support earlier recognition of clinically relevant changes when connected to professional oversight. The regulatory inclusion of software within the medical-device framework, combined with CDSCO’s current evaluation of sensor-based monitoring technologies for cardiovascular conditions, creates a pathway for increasingly sophisticated home-oriented devices. Connectivity, affordability, patient usability, data security, and integration with clinical workflows are therefore becoming important characteristics of this segment.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Cardiovascular Devices Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Device Type• Therapeutic and Surgical Devices• Diagnostic and Monitoring DevicesBy Application• Coronary Artery Disease (CAD) • Heart Failure • Cardiac Arrhythmia • Structural Heart Disease • Other ApplicationsBy End User• Hospitals & Cardiac Centers • Ambulatory Surgical Centers (ASCs) • Specialty Clinics • Home-Care Settings.